Skip to main navigation Skip to search Skip to main content

Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid

  • I. van't Erve
  • , K.P. Rovers
  • , A. Constantinides
  • , K. Bolhuis
  • , E.C.E. Wassenaar
  • , R.J. Lurvink
  • , C.J. Huysentruyt
  • , P. Snaebjornsson
  • , D. Boerma
  • , D. van den Broek
  • , T.E. Buffart
  • , M.J. Lahaye
  • , A.G. Aalbers
  • , N.F. Kok
  • , G.A. Meijer
  • , C.J. Punt
  • , O. Kranenburg
  • , I.H.J.T. de Hingh
  • , R.J.A. Fijneman*
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Tumor-derived cell-free DNA (cfDNA) is an emerging biomarker for guiding the personalized treatment of patients with metastatic colorectal cancer (CRC). While patients with CRC liver metastases (CRC-LM) have relatively high levels of plasma cfDNA, little is known about patients with CRC peritoneal metastases (CRC-PM). This study evaluated the presence of tumor-derived cfDNA in plasma and peritoneal fluid (i.e. ascites or peritoneal washing) in 20 patients with isolated CRC-PM and in the plasma of 100 patients with isolated CRC-LM. Among tumor tissue KRAS/BRAF mutation carriers, tumor-derived cfDNA was detected by droplet digital polymerase chain reaction (ddPCR) in plasma of 93% of CRC-LM and 20% of CRC-PM patients and in peritoneal fluid in all CRC-PM patients. Mutant allele fraction (MAF) and mutant copies per ml (MTc/ml) were lower in CRC-PM plasma than in CRC-LM plasma (median MAF = 0.28 versus 18.9%, p < 0.0001; median MTc/ml = 21 versus 1,758, p < 0.0001). Within patients with CRC-PM, higher cfDNA levels were observed in peritoneal fluid than in plasma (median MAF = 16.4 versus 0.28%, p = 0.0019; median MTc/ml = 305 versus 21, p = 0.0034). These data imply that tumor-derived cfDNA in plasma is a poor biomarker to monitor CRC-PM. Instead, cfDNA detection in peritoneal fluid may offer an alternative to guide CRC-PM treatment decisions.
Original languageEnglish
Pages (from-to)203-208
Number of pages6
JournalJournal of Pathology Clinical Research
Volume7
Issue number3
Early online date26 Feb 2021
DOIs
Publication statusPublished - May 2021

Keywords

  • ascitic fluid
  • biomarkers
  • circulating tumor dna
  • colorectal neoplasms
  • liquid biopsy
  • peritoneum
  • plasma
  • circulating tumor DNA

Fingerprint

Dive into the research topics of 'Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid'. Together they form a unique fingerprint.

Cite this